William Herrington

Has grant

Associate Professor

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

William Herrington is an Associate Professor at the University of Oxford, UK. His research primarily focuses on cardiovascular disease management in patients with diabetes and chronic kidney disease, as highlighted in his recent articles. He investigates the implications of SGLT2 inhibitors and other therapeutic interventions in relation to heart failure and metabolic syndrome, contributing significantly to global clinical guidelines in these areas.

Recent Grants

Grant: Close

MRC-Kidney Research UK Professor David Kerr Clinician Scientist

Open Date: 2018-02-01

Close Date: 2022-02-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (20)

Sofia Ahmed

University of Alberta

CANADA

William Herrington

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings

The prevention and management of chronic kidney disease among patients with metabolic syndrome

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns

Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study

Diabetic Kidney Disease — Semaglutide Flows into the Mainstream

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality

In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level

Body Composition and Risk of Vascular-Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease

Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study

Diabetes and infectious disease mortality in Mexico City

Bioimpedance in CKD: an untapped resource?

Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults.

Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology

Association of Kidney Function with NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults

Low-intensity daily smoking and cause-specific mortality in Mexico: Prospective study of 150 000 adults

Spinning the legs and blood: should intradialytic exercise be routinely offered during maintenance haemodialysis?

Collaborators (20)

Sofia Ahmed

Karen Robinson

Rasheeda K. Hall

Eirini Trichia

Rajiv Agarwal

Naveed Sattar

Federico Murgia

Patrick Mark

Bianca Rocca

Christoph Wanner

Diego Aguilar-Ramirez

Jennifer S Lees

Bethany J. Foster

Ramzi Ajjan

Kaitlin Mayne

Richard Haynes

Juan Jesus Carrero

Jonathan Emberson

Louisa Gnatiuc Friedrichs

Alexandra Kautzky-Willer

Make your next move.